drugset / Trial / NCT01616277
A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects
RandomizedParallel-groupDouble-blindBasic science
Summary
The purpose of this study is to determine if the study drug, PF-06252616 is safe and well tolerated when given to adult healthy volunteers.
Timeline
- Start
- 2012-06
- Primary completion
- 2014-08
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | PF-06252161 | Unknown | 10 mg/kg | Intravenous |
| Comparator | domagrozumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Comparator | domagrozumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Comparator | domagrozumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Comparator | domagrozumab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Comparator | domagrozumab | Monoclonal antibody | 40 mg/kg | Intravenous |
Indications
No indication recorded.